Cowen Starts Avalanche Biotechnologies (AAVL) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
William Blair Starts Avalanche Biotechnologies (AAVL) at Outperform
August 25, 2014 7:12 AM EDTWilliam Blair initiated coverage on Avalanche Biotechnologies (NASDAQ: AAVL) with an Outperform rating.
For an analyst ratings summary and ratings history on Avalanche Biotechnologies click here. For more ratings news on Avalanche Biotechnologies click here.
Shares of Avalanche Biotechnologies closed at $30.52 yesterday.
... MoreJefferies Starts Avalanche Biotechnologies (AAVL) at Buy
August 25, 2014 6:55 AM EDTJefferies initiates coverage on July IPO Avalanche Biotechnologies (NASDAQ: AAVL) with a Buy rating and a price target of $40.00.
Analyst Biren Amin said, "AAVL shares hold significant promise based on PI data with AVA-101 observing meaningful VA improvements and durable responses in wAMD... More
Piper Jaffray Starts Avalanche Biotechnologies (AAVL) at Overweight
August 25, 2014 6:53 AM EDTPiper Jaffray initiates coverage on July IPO Avalanche Biotechnologies (NASDAQ: AAVL) with a Overweight rating and a price target of $39.00.
Analyst Joshua Schimmer comments, "The company is among a handful of pioneers in the gene therapy field, and a leader among an even... More
